BCL2 and posterior cortical atrophy: Targeting the anti-apoptotic BCL2 proteins, with small molecule BH3 mimetics, antibody drug conjugates (ADC) and proteolysis targeting chimeras (PROTAC), to breach the apoptotic threshold, is an attractive therapeutic strategy for lethal PCa.6